Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 20/20 | 0.70 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833020 | 1.00 | MAP4K1 (0.70) | MAP4K1MAP4K3 | |
| SCHEMBL24620500 | 1.00 | MAP4K1 (0.70) | MAP4K1MAP4K3 | |
| SCHEMBL30833017 | 0.89 | MAP4K1 (0.68) | MAP4K1 | |
| SCHEMBL30833048 | 0.89 | MAP4K1 (0.68) | MAP4K1 | |
| SCHEMBL24620201 | 0.89 | MAP4K1 (0.68) | MAP4K1 | |
| SCHEMBL24620274 | 0.89 | MAP4K1 (0.68) | MAP4K1 | |
| SCHEMBL24620221 | 0.89 | MAP4K1 (0.53) | MAP4K1 | |
| SCHEMBL24620306 | 0.87 | ALK (0.52) | MAP4K1 | |
| SCHEMBL24620173 | 0.87 | ALK (0.52) | MAP4K1 | |
| SCHEMBL24620188 | 0.82 | MAP4K1 (0.56) | MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | claimed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | MAP4K1 55/4885MAP4K3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.